Industry-sponsored satellite symposia at the 23rd EURETINA Congress

News
Article

Attendees can take advantage of many satellite symposia, sponsored by industry and feauring experts from around the world

A bridge and bicycles in Amsterdam. Image credit: ©andreykr – stock.adobe.com

During the EURETINA congress, there will be 1-hour symposia sessions on Thursday, Friday and Saturday. Image credit: ©andreykr – stock.adobe.com

The 23rd annual EURETINA Congress will be held from October 5 to October 7 in Amsterdam, the Netherlands. The venue is RAI Amsterdam.

In addition to the numerous educational opportunities offered by the Congress program, attendees also can take advantage of many satellite symposia sponsored by industry. Experts from around the world will present during the symposia.

The following are the titles of the 1-hour symposia sessions. All times listed are expressed in Central European Summer Time (CEST).

Thursday October 5

  • 13:30 – 14:30 CEST: Change in treatment paradigm for DME with faricimab: Evidence from clinical trials and real-world practice (sponsored by Roche)

Friday October 6

  • 09:45 - 10:45 CEST: Eye to Eye - Maximize your surgical approach (sponsored by Alcon)
  • 09:45 - 10:45 CEST: Current management of inherited retinal diseases: the X-linked retinitis pigmentosa perspective (sponsored by Janssen)
  • 09:45 - 10:45 CEST: Have we maximised patient outcomes, or can we go further? (sponsored by Bayer)
  • 13:45 - 14:45 CEST: Modern imaging and algorithms for interrogating chorioretinal disease (sponsored by Nidek)
  • 13:45 - 14:45 CEST: Exploring diabetic macular edema: clinical considerations and perspectives on its management (sponsored by Novartis)
  • 13:45 - 14:45 CEST: Informed decision-making every step of the way - PART 1 : Diagnostic imaging in disease management (sponsored by Zeiss)
  • 13:45 - 14:45 CEST: Change in treatment paradigm for nAMD with faricimab: Evidence from clinical trials and real-world practice (sponsored by Roche)
  • 13:45 - 14:45 CEST: Advances in ultra-widefield multimodal retinal imaging - learn from our experts (sponsored by Optos)
  • 17.45 - 18.45 CEST: The future of continuous drug delivery for retinal diseases (sponsored by Roche)

Saturday October 7

  • 10:15 - 11:15 CEST: Is sustained disease control the new benchmark for patient care? (sponsored by Bayer)
  • 10:15 - 11:15 CEST: Laser for retina and vitreous: All you need to know in 2023 (sponsored by Lumibird)
  • 10:15 - 11:15 CEST: Informed decision-making every step of the way - Part 2: Visualization in vitreoretinal surgery (sponsored by Zeiss)
  • 10:15 - 11:15 CEST: Discovering ChANGe with Ang-2 (sponsored by Roche)
  • 10:15 - 11:15 CEST: IME: Dry AMD & GA IME Platform: practical considerations for GA treatment (sponsored by the Euretina Education Platform)
  • 13:00 - 14:00 CEST: Geographic atrophy: navigating to the future (sponsored by Apellis)
  • 13:00 - 14:00 CEST: What is Bayer’s vision for the future of ophthalmology? (sponsored by Bayer)
  • 13:00 - 14:00 CEST: New dimensions in visualization: changing the way you look (sponsored by Bausch & Lomb)
  • 13:00 - 14:00 CEST: High-resolution OCT in retinal disorders including atrophic AMD (sponsored by Heidelberg Engineering)
  • 13:00 - 14:00 CEST: LIGHTSITE III pivotal trial 24-month analysis: multiwavelength Valeda® Light Delivery System Treatment in early/intermediate dry age-related macular degeneration patients(sponsored by LumiThera)
  • 18:00 - 19:00 CEST: Retinale® - EURETINA Kompakt (sponsored by Roche)
Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.